We are live on ! Find out more
TERN

Terns Pharmaceuticals
TERN

Delisted

TERN was delisted on the 4th of May, 2026.

Back to rankings

156 hedge funds and large institutions have $663M invested in Terns Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 53 funds opening new positions, 53 increasing their positions, 37 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

130% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 23

96% more call options, than puts

Call options by funds: $8.73M | Put options by funds: $4.45M

48% more capital invested

Capital invested by funds: $447M → $663M (+$216M)

43% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 37

24% more funds holding

Funds holding: 126 → 156 (+30)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

7.24% less ownership

Funds ownership: 101.4% → 94.16% (-7.2%)

Holders
156
Holders Change
+30
Holders Change %
+23.81%
% of All Funds
2.24%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
53
Increased
53
Reduced
37
Closed
23
Calls
$8.73M
Puts
$4.45M
Net Calls
+$4.28M
Net Calls Change
+$1.38M

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$18.2M
2
APM
Avidity Partners Management
Texas
+$17.6M
3
ECM
ExodusPoint Capital Management
New York
+$13.6M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$11.9M
5
SCM
Soleus Capital Management
Connecticut
+$10.5M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$13.1M
2
OCA
Octagon Capital Advisors
New York
-$9.29M
3
GPP
Great Point Partners
Connecticut
-$7.83M
4
Franklin Resources
Franklin Resources
California
-$7.65M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$6.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
AAA
26
Affinity Asset Advisors
New York
$5M +$4.94M +600,000 New
PHP
27
Parkman Healthcare Partners
Connecticut
$4.55M +$1.28M +155,481 +40%
Deutsche Bank
28
Deutsche Bank
Germany
$4.53M +$3.67M +445,668 +459%
ACP
29
Acuta Capital Partners
California
$4.06M +$969K +117,720 +32%
Renaissance Technologies
30
Renaissance Technologies
New York
$4M +$3.23M +392,000 +448%
Northern Trust
31
Northern Trust
Illinois
$3.87M +$955K +116,108 +33%
Qube Research & Technologies (QRT)
32
Qube Research & Technologies (QRT)
United Kingdom
$3.81M +$3.76M +456,939 New
SC
33
Stempoint Capital
New York
$3.75M +$3.7M +449,321 New
Goldman Sachs
34
Goldman Sachs
New York
$3.49M -$2.3M -279,847 -40%
SIC
35
Salem Investment Counselors
North Carolina
$3.14M +$41.1K +5,000 +1%
ACM
36
Altium Capital Management
New York
$2.75M +$2.72M +330,000 New
IC
37
Ikarian Capital
Texas
$2.57M -$1.23M -150,000 -33%
TI
38
Trexquant Investment
Connecticut
$2.53M +$2.22M +270,193 +801%
WP
39
Woodline Partners
California
$2.51M -$3.65M -443,820 -60%
IHAM
40
Integral Health Asset Management
New York
$2.5M +$2.47M +300,000 New
TAM
41
Telemark Asset Management
Massachusetts
$2.5M +$2.47M +300,000 New
AllianceBernstein
42
AllianceBernstein
Tennessee
$2.04M -$440K -53,488 -18%
Wellington Management Group
43
Wellington Management Group
Massachusetts
$1.85M -$17.4K -2,111 -0.9%
JGC
44
J. Goldman & Co
New York
$1.7M +$1.68M +203,941 New
SB
45
Samsara BioCapital
California
$1.69M – – –
CSS
46
Cubist Systematic Strategies
Connecticut
$1.56M +$1.54M +186,578 New
Walleye Capital
47
Walleye Capital
New York
$1.55M +$1.53M +185,795 New
CCM
48
Cinctive Capital Management
New York
$1.41M +$1.39M +168,564 New
Bank of New York Mellon
49
Bank of New York Mellon
New York
$1.35M -$126K -15,295 -9%
Voloridge Investment Management
50
Voloridge Investment Management
Florida
$1.32M +$1.3M +157,786 New
1
2
3 4 5

TERN Hedge Fund Activity: Q3 2024 in Review

156 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q3 2024, worth a combined $663M — up 48% from $447M a quarter earlier.

Buyers outnumbered sellers: 53 funds opened new TERN positions and 23 closed out — a net gain of 30 holders — while 53 added to existing stakes and 37 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $18.2M. The largest seller was Fidelity Investments, cutting an estimated $13.1M.

  • 156 institutional investors held Terns Pharmaceuticals (TERN) as of Q3 2024, up from 126 in Q2 2024.
  • Funds reported $663M of Terns Pharmaceuticals stock for Q3 2024, up 48% quarter-over-quarter.
  • 53 funds opened new Terns Pharmaceuticals positions in Q3 2024 and 23 closed out, a net change of +30 holders.
  • The largest Terns Pharmaceuticals buyer in Q3 2024 was Citadel Advisors, an estimated $18.2M added.
  • The largest Terns Pharmaceuticals seller in Q3 2024 was Fidelity Investments, an estimated $13.1M sold.

Based on aggregated 13F filings for Q3 2024.